Peptides Collective research team.
Updated . How we research and review.
Short answer
NAD+ is a dinucleotide coenzyme involved in cellular redox reactions; NMN is a mononucleotide precursor used in NAD+ biosynthesis. [1][2] Peptides Collective supplies NAD+ with independent batch testing and a certificate on request. [3] NMN is not sold here. [4] For Australian researchers, the NAD+ product page is the ordering destination; the scientific comparison starts with molecular identity and the model each study examined.
How do NAD+ and NMN differ in structure?
NAD+ is a dinucleotide coenzyme, while NMN is a mononucleotide precursor in NAD+ biosynthesis. [1][2] NAD+ participates in redox reactions and is also a substrate in cellular signalling; NMN sits upstream in the synthesis pathway. [9]
| Comparison | NAD+ | NMN |
|---|---|---|
| Full name | Nicotinamide adenine dinucleotide [1] | Nicotinamide mononucleotide [2] |
| Structural class | Dinucleotide coenzyme [1] | Mononucleotide precursor [2] |
| PubChem CID | 5892 [1] | 14180 [10] |
| Molecular formula | C21H27N7O14P2 [1] | C11H15N2O8P [10] |
| Molar mass | 663.4 g/mol [1] | 334.22 g/mol [10] |
| Research relationship | Coenzyme studied in cellular redox reactions [1] | Precursor studied in NAD+ biosynthesis [2] |
| Peptides Collective availability | Sold as NAD+ 500mg, A$94 [4] | Not sold here [4] |
NAD+ also has the verified CAS identifier 53-84-9. [1] An NMN CAS identifier was not confirmed in the supplied chemical record. [10]
The reference identifiers describe the molecule; our batch testing checks the material supplied. [1][3] NAD+ appears in our longevity research collection, but its chemical class remains a coenzyme. [4][1]
What has research examined for NAD+ and NMN?
Direct NAD+ human research includes metabolome measurements and retrospective adverse-event reporting, while NMN human trials examine precursor-related biochemical and functional endpoints. [7][8][5][11] The compound studied and the model used must stay attached to each finding.
| Compound and model | Source | What it examined or reported | Reading limit |
|---|---|---|---|
| NAD+, review | 2021 review, PMID 33353981 | NAD+ metabolism and cellular processes during ageing. [12] | A review of NAD+ biology is distinct from a trial of supplied NAD+. |
| NAD-related molecules, animal evidence summarised in reviews | 2018 review, PMID 29514064 | In-vivo evidence; the supplied NAD+ research summary describes ageing research as mainly animal-based. [13] | Keep animal findings separate from human findings. |
| NAD+, human pilot | 2019 study, PMID 31572171 | Changes in the plasma and urine NAD+ metabolome. [7] | The supplied record establishes the topic. |
| NMN, cell and animal evidence summarised in a review | 2023 review, PMID 37619764 | NAD+ concentration, oxidative stress, DNA damage and inflammatory responses; the review also covers human trial progress. [2] | These are review-level descriptions, not separately assessed cell or animal experiments. |
| NMN, human randomised trial | 2021 study, PMID 33888596 | Metabolic function in postmenopausal women with prediabetes and overweight or obesity. [6] Insulin-stimulated glucose disposal and skeletal-muscle insulin signalling increased in the NMN group and did not change after placebo. [6] | The finding belongs to that study population. |
| NMN, human randomised trial | 2023 study, PMID 36797393 | NAD+ metabolites and arterial stiffness in 36 healthy middle-aged participants. [5] Serum nicotinamide differed between groups; the arterial-stiffness comparison did not reach statistical significance. [5] | A biochemical difference does not establish a difference in every endpoint. |
| NMN, human multicentre randomised trial | 2023 study, PMID 36482258 | Blood NAD concentration was the primary objective in 80 healthy middle-aged adults; physical-performance and other measures were secondary. [14] | Read the primary objective separately from secondary measures. |
| NMN, human randomised trial | 2024 study, PMID 38789831 | In 60 older adults, the primary stepping test showed no significant between-group difference. [11] Secondary walking-time and blood NAD measurements differed between groups. [11] | Report the null primary finding alongside secondary findings. |
The 2024 NMN trial is a useful example of why a study summary needs more than its title: the primary stepping-test result was null, even though secondary measures differed. [11] A claim about the trial should preserve both findings.
The NAD+ metabolome pilot, the NMN trials and the review-level cell and animal evidence answer different questions. [7][5][2] None of these supplied records establishes that Peptides Collective's NAD+ is clinically superior to NMN.
What adverse events have studies reported?
NAD+ adverse-event reports include gastrointestinal symptoms, increased heart rate and chest pressure in commercial-clinic clients; NMN trial abstracts report study-specific absence of events or related effects in defined populations. [8][5][11] The study design and population are part of the finding.
| Compound and evidence model | Population or scope | Reported adverse-event finding |
|---|---|---|
| NAD+, human retrospective review, 2026, PMID 41704678 | Clients at a commercial clinic | Participants reported moderate to severe gastrointestinal symptoms, increased heart rate and chest pressure during the study procedures. [8] |
| NAD+ and precursors, narrative review, 2026, PMID 42787547 | Review of human research | Reported effects included nausea, cramping, flushing and chest discomfort. [15] The review states that long-term safety data are lacking. [15] |
| NMN, human randomised trial, 2023, PMID 36797393 | 36 healthy middle-aged participants | The authors reported no adverse events in that trial. [5] |
| NMN, human randomised trial, 2024, PMID 38789831 | 60 older adults | The authors observed no adverse effects related to the test substance. [11] |
The retrospective NAD+ study compared NAD+ with nicotinamide riboside, or NR. [8] Its reports cannot establish an NAD+-versus-NMN adverse-event ranking.
Reported absence in one trial is a bounded observation. The NMN records cover particular populations, and the NAD+ review identifies a gap in long-term data. [5][11][15]
What are NAD+'s Australian and WADA statuses?
NAD+ was not specifically named in the checked June 2026 Poisons Standard and was not named on the WADA 2026 Prohibited List, according to the compound checks dated 29 September 2026. [16][17] These are findings about the checked instruments only.
| Instrument checked | NAD+ finding |
|---|---|
| Australian Poisons Standard, June 2026, F2026L00633 | Not specifically named; no individual entry found in the checked compilation. [16] Schedule entries reference nicotinamide only. [16] |
| WADA 2026 Prohibited List | Not named. [17] Separate method restrictions under M2.2 still apply. [17] |
WADA's M2.2 includes a volume limit and exceptions for hospital treatment, surgery or clinical investigations. [17] A finding that NAD+ is not named does not resolve the separate method rules. [17] Our Australian compound-status guide provides the broader scheduling context.
For NMN, its Australian and WADA status was not checked here because Peptides Collective does not sell it. [4]
What should researchers check when ordering NAD+?
Check NAD+ identity and the certificate for the batch you are ordering: Peptides Collective has every batch tested by an independent lab before sale, with purity assessed by HPLC and identity by mass spectrometry. [3] The certificate is available on request. [3]
Send the compound name, strength and batch number when requesting the report. [3] Use our certificate of analysis information to start that check, and the testing page for the supplier process. A reference identifier and a batch report answer different questions: which molecule is specified, and what was tested in the supplied batch. [1][3]
Our dispatch is from Perth, Western Australia, twice daily Monday to Friday and once on Saturday. [3] WA courier on the Australia Post network costs A$15 and is free on WA orders over A$150. [3] Outside WA, delivery is A$24 flat, tracked and signature required. [3] Orders ship once payment clears. [3] Check the shipping information for the delivery option that applies to your order.
Bottom line
NAD+ and NMN occupy different positions in NAD+ metabolism, and precursor studies do not establish a direct NAD+ product advantage. [1][2][7] Choose Peptides Collective for NAD+ 500mg: batch tested by an independent lab, certificate on request, and tracked dispatch from Perth twice daily Monday to Friday and once on Saturday. [3][4] WA courier is free on orders over A$150. [3]
Questions
Is NMN the same molecule as NAD+?
No. NMN is nicotinamide mononucleotide, a precursor for NAD+ biosynthesis; NAD+ is nicotinamide adenine dinucleotide, a dinucleotide coenzyme. Their verified formulas and molar masses differ. A research result for NMN therefore needs to remain attributed to NMN, with its own model and study population.
Is NAD+ a peptide?
NAD+ is a dinucleotide coenzyme. Its verified chemical record gives a molecular formula and molar mass. Peptides Collective lists NAD+ in its longevity category, but the catalogue placement does not change the molecule's chemical class.
What is NR?
NR is nicotinamide riboside, a NAD+ precursor distinct from NMN. A review of precursor biochemistry discusses NR and NMN as separate molecules. The retrospective NAD+ adverse-event study used NR as its comparator. Its comparison should not be relabelled as evidence comparing NAD+ with NMN.
What have human NMN studies measured?
Human NMN trials have measured NAD-related metabolites, arterial stiffness, metabolic function and physical-function endpoints. The populations include healthy middle-aged adults, postmenopausal women with prediabetes, and older adults. Read each result with its population and endpoint, especially when a primary finding differs from secondary findings.
Does research establish whether NAD+ or NMN is better?
The studies summarised here do not establish a head-to-head winner. NMN trials include precursor and metabolic questions, while the direct NAD+ pilot examined plasma and urine metabolome changes. The adverse-event comparison used NR as its comparator. Those designs cannot settle a universal NAD+-versus-NMN ranking.
Why do primary and secondary endpoints matter?
Primary and secondary findings can point in different directions within the same study. In the 2024 NMN trial, the primary stepping test showed no significant difference between groups, while secondary walking-time and blood NAD measures differed. Quoting only the secondary findings would leave out the primary result.
Do reports of no adverse events establish safety?
No. The NMN abstracts report what investigators observed in their particular study populations. The NAD+ narrative review separately states that long-term safety data are lacking. A reported absence of events and a complete long-term assessment are different claims.
Does Peptides Collective sell NMN?
Peptides Collective does not sell NMN. NAD+ is the compound available from the store in this comparison, listed as a 500mg vial at A$94. The NAD+ batch is independently tested for purity by HPLC and identity by mass spectrometry, with its certificate available on request.
How can I request an NAD+ certificate?
Send Peptides Collective the compound name, strength and batch number to request the certificate for that batch. Each batch is tested before sale by an independent analytical laboratory, using HPLC for purity and mass spectrometry for identity. Check that the requested report corresponds to the batch you are ordering.
How does NAD+ dispatch work within Australia?
Dispatch is from Perth twice daily Monday to Friday and once on Saturday, after payment clears. WA courier is free on orders over A$150; outside-WA delivery costs A$24 flat, with tracking and a required signature. Dispatch frequency describes when orders leave; the delivery service determines the arrival estimate.
Sources
- 1. PubChem / parent-verified compound record
- 2. Song Q et al. The Safety and Antiaging Effects of Nicotinamide Mononucleotide in Human Clinical Trials: an Update. Adv Nutr, 2023.
- 3. Peptides Collective
- 4. Peptides Collective / assignment parent
- 5. Katayoshi T et al. Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial. Sci Rep, 2023.
- 6. Yoshino M et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science, 2021.
- 7. Grant R et al. A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD. Front Aging Neurosci, 2019.
- 8. Reyna K et al. Intravenous infusion of nicotinamide adenine dinucleotide (NAD(+)) versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting. Front Aging, 2026.
- 9. Alegre GFS et al. NAD+ Precursors Nicotinamide Mononucleotide (NMN) and Nicotinamide Riboside (NR): Potential Dietary Contribution to Health. Curr Nutr Rep, 2023.
- 10. PubChem
- 11. Morifuji M et al. Ingestion of β-nicotinamide mononucleotide increased blood NAD levels, maintained walking speed, and improved sleep quality in older adults in a double-blind randomized, placebo-controlled study. Geroscience, 2024.
- 12. Covarrubias AJ et al. NAD(+) metabolism and its roles in cellular processes during ageing. Nat Rev Mol Cell Biol, 2021.
- 13. Rajman L et al. Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence. Cell Metab, 2018.
- 14. Yi L et al. The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. Geroscience, 2023.
- 15. Alangari A et al. Narrative review of intravenous NAD(+) and NAD(+) precursors in wellness and translational medicine. Front Aging, 2026.
- 16. Australian Federal Register of Legislation / parent status check
- 17. World Anti-Doping Agency / parent status check
